Multiply Labs and Wilson Wolf Join Forces to Automate Cell Therapy Manufacturing with G-Rex® Bioreactors

Standardization, Simplification, and Cost Reduction for Lifesaving Therapies

We’re excited to announce a collaborative effort between Multiply Labs, a leader in automated manufacturing systems for personalized medicine, and Wilson Wolf Corporation, a pioneer in cell and gene-modified therapy (CGT) technology. This partnership focuses on automating Wilson Wolf’s innovative G-Rex® bioreactors, aiming to revolutionize CGT manufacturing.

Shared Vision for Accessible Therapies

Both Multiply Labs and Wilson Wolf share a commitment to making potentially lifesaving cell and gene therapies more accessible. This collaboration will achieve this goal by:

• Standardization: Simplifying the CGT manufacturing process through automation, reducing reliance on highly skilled labor.
• Cost Reduction: Lowering manufacturing costs, making these therapies more affordable for patients.
• High-Throughput Manufacturing: Enabling large-scale production using a “ballroom” setting with automated G-Rex® bioreactors.

G-Rex®: An ideal Platform for Automation

Wilson Wolf’s G-Rex® bioreactors are uniquely suited for automation due to their:

• Closed System Design: Provides cells with continuous oxygen and nutrients, eliminating the need for manual intervention.
• All-in-One Functionality: Acts as a single unit for activation, transduction, expansion, and concentration, simplifying the manufacturing process.
• High Throughput Potential: Enables seamless integration with automated systems for large-scale production.

Scientific Validation and Industry Recognition

Multiply Labs’ robotic system, designed for T cell therapy expansion with G-Rex® bioreactors, has received validation through a peer-reviewed publication in Cytotherapy, a leading journal in the field. Industry estimates suggest this technology has the potential to reduce cell therapy manufacturing costs by a staggering 70%.

The Future of Cell Therapy Manufacturing

This collaboration between Multiply Labs and Wilson Wolf Corporation represents a significant leap forward in cell therapy manufacturing. By automating G-Rex® bioreactors, we pave the way for increased accessibility of these life-saving treatments to a broader patient population.

Stay tuned for further updates on this exciting partnership and its impact on the future of cell and gene therapy!